CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: February 20, 2020
Result type: Reports
Project Number: SR0629-000
Product Line: Reimbursement Review

Generic Name: etonogestrel

Brand Name: TBC

Manufacturer: Merck Canada Inc.

Therapeutic Area: Prevention of pregnancy

Indications: Prevention of pregnancy

Manufacturer Requested Reimbursement Criteria1: For the prevention of pregnancy as an open benefit without restrictions

Submission Type: Initial

Project Status: Withdrawn

Companion Diagnostics: No

Fee Schedule: Schedule A

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient input postedAugust 16, 2019
Patient group input closedOctober 07, 2019

- No patient input submission received

Submission receivedSeptember 26, 2019
Submission acceptedOctober 10, 2019
Review initiatedOctober 11, 2019
Draft CADTH review report(s) sent to sponsorJanuary 03, 2020
Comments from sponsor on draft CADTH review report(s) receivedJanuary 14, 2020
CADTH review team's comments on draft CADTH review report(s) sent to sponsorFebruary 06, 2020

Withdrawn on 19 Feb 2020